The Problem
About 10% of patients with advanced kidney cancer develop a life-threatening complication: their tumors produce a hormone that sends blood calcium levels dangerously high. Hypercalcemia causes confusion, seizures, muscle weakness, and in severe cases, cardiac arrhythmias. Standard treatment with bisphosphonates carries its own risks—osteonecrosis of the jaw, fractures, even rebound hypocalcemia. For decades, clinicians have managed this as a side effect. Researchers at UT Southwestern asked a different question: what if we could stop the tumor from making the hormone in the first place?
The Finding in Plain Terms
Researchers at UT Southwestern identified that kidney cancer cells hijack a master metabolic regulator called HIF-2 (hypoxia-inducible factor 2) to produce excessive amounts of PTHrP, a hormone that tells the body to raise blood calcium. The discovery came from pairing cell and animal experiments with patient data: in aggressive clear-cell renal cell carcinomas, HIF-2 directly activates the gene that produces PTHrP.
When researchers used a drug that blocks HIF-2 (belzutifan, also known as PT2977), calcium levels dropped rapidly—sometimes within days—in both mouse models and in real kidney cancer patients with hypercalcemia. Crucially, the drug worked even in patients whose tumors didn’t shrink, suggesting hypercalcemia could be treated as a targetable side effect independent of overall tumor control.
Why It Matters
Paraneoplastic syndromes (symptoms caused not by tumor growth itself but by substances the tumor produces) have long been the forgotten cousins of oncology. Hypercalcemia in kidney cancer is a marker of aggressive disease and poor prognosis, but the standard approach is to suppress calcium levels after the fact, not to address the root cause. This work reframes the problem: if you understand the molecular mechanism driving the hormone production, you can intervene upstream.
The HIF-2-PTHrP axis was already suspected to be important in kidney cancer—clear-cell renal cell carcinoma is driven by loss of the VHL tumor suppressor, which leads to HIF-2 accumulation. But showing that HIF-2 directly controls PTHrP transcription, and that blocking HIF-2 rapidly resolves hypercalcemia, bridges laboratory mechanism to clinical benefit.
For patients, this could mean a way to address hypercalcemia that avoids the cumulative toxicities of bisphosphonates. For drug developers, it validates HIF-2 inhibitors as tools for managing not just tumor growth but also metabolic derangements that drive morbidity and mortality.
How They Did It
The team led by James Brugarolas at UT Southwestern used multiple complementary approaches. They started with patient data: reviewing cases of advanced kidney cancer with hypercalcemia and measuring PTHrP levels. In the lab, they used CRISPR and other tools to confirm that HIF-2 directly activates the PTHLH gene (which encodes PTHrP). They validated the pathway in preclinical models: mice transplanted with human kidney cancer cells showed rapid calcium normalization when treated with the HIF-2 inhibitor PT2399, with symptoms like weight loss and fatigue improving within days. Finally, they presented a clinical case study of a 63-year-old man with advanced clear-cell renal cell carcinoma who experienced rapid resolution of hypercalcemia and normalization of PTHrP levels when treated with belzutifan, without the side effects of standard bisphosphonate therapy.
Limitations and Caveats
This is early-stage translational work, not a completed clinical trial. The clinical evidence consists of preclinical mouse models and a single patient case study, not a randomized controlled trial or even a multi-patient cohort analysis. Hypercalcemia itself is a paraneoplastic complication that only affects a subset of advanced kidney cancer patients (roughly 10%), so the generalizability to the broader kidney cancer population is limited. The authors did not evaluate long-term toxicity of HIF-2 inhibition for this indication, and HIF-2 inhibitors are still in development for cancer in general. Additionally, belzutifan is an allosteric inhibitor with off-target effects that could complicate attribution of benefit to HIF-2 inhibition alone. The work is strong mechanistically, but clinical validation will require prospective trial data.
What This Means in Practice
For kidney cancer patients: If you develop hypercalcemia during treatment, this work suggests HIF-2 inhibitors may offer an alternative to bisphosphonates, with potentially fewer cumulative side effects. However, this is not yet standard clinical practice and would require enrollment in a trial or compassionate use.
For oncologists: Paraneoplastic hypercalcemia in clear-cell renal cell carcinoma should prompt consideration of HIF-2 inhibitor therapy as a mechanism-based intervention, not just standard symptom management.
For researchers: This study exemplifies how understanding the transcriptional and metabolic logic of a cancer-driven pathway can convert a complication into a druggable vulnerability. It suggests other HIF-2-driven paraneoplastic syndromes in kidney cancer (weight loss, fatigue, metabolic derangement) may respond similarly to HIF-2 blockade.
For drug developers: HIF-2 inhibitors now have clinical evidence of benefit in a subset of kidney cancer patients defined by a molecular marker (PTHrP elevation and hypercalcemia). This could accelerate registration trials and patient stratification.
Source and Further Reading
Mal, A., Xie, B., Gray, Z., et al. (2025). HIF-2-Dependent Regulation of PTHrP and Paraneoplastic Hypercalcemia in Aggressive Clear-Cell Renal Cell Carcinoma. Cancer Discovery, 15(12), 2485–2504. Published October 9, 2025.
Related institutional research: UT Southwestern Kidney Cancer Program
What’s Next
This work sets the stage for prospective clinical trials testing HIF-2 inhibitors specifically in kidney cancer patients with hypercalcemia as the primary endpoint. Such trials would establish whether HIF-2 blockade becomes a first-line management strategy, potentially sparing patients from long-term bisphosphonate toxicity while also addressing the underlying driver of this aggressive metabolic complication.
See Also
- Spatial Omics Reveals Hidden Aggression Signals in Prostate Tumors — How multi-dimensional approaches are uncovering tumor heterogeneity and metastatic potential
- How Scientists Finally Made Helper T Cells From Stem Cells — Translating basic immunology into cell therapy that works